Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Treating Duchenne Muscular Dystrophy and Carrier-Associated Pathologies.

Atossa Therapeutics announces emerging opportunity for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD) treatment. A peer-reviewed publication and upcoming scientific presentation highlight the potential for (Z)-endoxifen to address multiple drivers of disease, including inflammation, fibrosis, and mitochondrial dysfunction. The therapy's direct estrogen-receptor modulation and allosteric inhibition of PKC may help slow disease progression.